X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SUVEN LIFESCIENCES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SUVEN LIFESCIENCES ASTRAZENECA PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 87.8 20.8 422.2% View Chart
P/BV x 19.4 4.1 476.0% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
SUVEN LIFESCIENCES
Mar-18
ASTRAZENECA PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,278251 509.6%   
Low Rs883155 569.4%   
Sales per share (Unadj.) Rs228.449.1 464.9%  
Earnings per share (Unadj.) Rs10.49.7 106.7%  
Cash flow per share (Unadj.) Rs16.311.4 142.7%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs98.860.3 163.8%  
Shares outstanding (eoy) m25.00127.28 19.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.1 114.5%   
Avg P/E ratio x104.220.9 499.2%  
P/CF ratio (eoy) x66.417.8 373.0%  
Price / Book Value ratio x10.93.4 325.0%  
Dividend payout %015.4 0.0%   
Avg Mkt Cap Rs m27,00825,825 104.6%   
No. of employees `0001.41.1 126.5%   
Total wages/salary Rs m1,535613 250.6%   
Avg. sales/employee Rs Th4,210.95,832.6 72.2%   
Avg. wages/employee Rs Th1,132.2571.5 198.1%   
Avg. net profit/employee Rs Th191.11,153.8 16.6%   
INCOME DATA
Net Sales Rs m5,7106,253 91.3%  
Other income Rs m123233 52.6%   
Total revenues Rs m5,8336,485 89.9%   
Gross profit Rs m4631,982 23.4%  
Depreciation Rs m147213 69.2%   
Interest Rs m046 0.0%   
Profit before tax Rs m4381,955 22.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179718 24.9%   
Profit after tax Rs m2591,237 20.9%  
Gross profit margin %8.131.7 25.6%  
Effective tax rate %40.836.7 111.2%   
Net profit margin %4.519.8 22.9%  
BALANCE SHEET DATA
Current assets Rs m3,2095,622 57.1%   
Current liabilities Rs m2,0701,168 177.2%   
Net working cap to sales %20.071.2 28.0%  
Current ratio x1.64.8 32.2%  
Inventory Days Days7281 88.8%  
Debtors Days Days3536 97.2%  
Net fixed assets Rs m7903,325 23.8%   
Share capital Rs m50127 39.3%   
"Free" reserves Rs m2,4197,547 32.1%   
Net worth Rs m2,4697,674 32.2%   
Long term debt Rs m014 0.0%   
Total assets Rs m4,6059,135 50.4%  
Interest coverage xNM43.2-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.7 181.1%   
Return on assets %5.614.0 40.1%  
Return on equity %10.516.1 65.1%  
Return on capital %17.726.0 68.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3005,066 5.9%   
Fx outflow Rs m2,0152,001 100.7%   
Net fx Rs m-1,7153,065 -56.0%   
CASH FLOW
From Operations Rs m88699 12.6%  
From Investments Rs m-94-6 1,534.4%  
From Financial Activity Rs mNA-577 0.0%  
Net Cashflow Rs m-6116 -4.9%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.5 24.9%  
Shareholders   12,856 37,287 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  PANACEA BIOTECH  WOCKHARDT  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens on a Strong Note Tracking Global Cues; Metal & Realty Stocks Lead(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.7% while the Hang Seng is up 2.4%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 19, 2019 10:43 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS